Malaria Control in Kenya: Disease Burden, the National Malaria Strategy, the Insecticide-Treated Net Programme and the Path to Elimination

Malaria remains one of the most significant public-health challenges in Kenya, with the World Health Organization (WHO) and the Kenya Ministry of Health estimating approximately 3.5 million clinical cases annually producing approximately 10,700 deaths, with children under five and pregnant women bearing disproportionate disease burden. Approximately 70 per cent of the Kenyan population lives in malaria-endemic or malaria-epidemic zones, with the high-transmission areas concentrated in the Lake Victoria basin (Kisumu, Siaya, Homa Bay, Migori, Busia, Vihiga, Kakamega, and Bungoma counties), the Coast (Kilifi, Kwale, Mombasa, Lamu, Tana River, Taita Taveta counties), and selected lower-altitude inland areas. The principal malaria vector species in Kenya are Anopheles gambiae sensu stricto, Anopheles arabiensis, and Anopheles funestus, with Plasmodium falciparum accounting for approximately 99 per cent of malaria cases — the most dangerous of the human malaria parasite species. The National Malaria Programme, operating under the Ministry of Health and the Division of National Malaria Programme (DNMP) coordinates the malaria-control interventions across the country, supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria, the President's Malaria Initiative (PMI) of the US Government, and the broader development partner community. This guide walks through the disease burden, the principal control interventions, the National Malaria Strategy, the broader research and innovation work, and the path toward malaria elimination.

Disease Burden

Malaria accounts for approximately 19 per cent of outpatient consultations in Kenya's public health facilities — making malaria one of the principal disease-burden drivers at the primary-care level. Children under five account for the majority of severe malaria cases and malaria deaths, with the broader vulnerable populations (pregnant women, people living with HIV, malnourished children) also experiencing disproportionate severe-disease burden. The economic cost of malaria — through medical treatment, lost productivity, school absences, and the broader societal impact — is estimated at substantial percentages of household income in endemic areas.

The National Malaria Strategy

The Kenya National Malaria Strategy, periodically updated through five-year cycles, sets out the integrated framework for malaria control. The most recent Strategy (covering the 2019-2025 period) targets substantial reductions in malaria incidence and mortality through the integrated package of interventions including vector control, case management, prevention in pregnancy, surveillance, and the broader supportive interventions. The Strategy is implemented through the DNMP and the County Health Departments under the devolution framework, with substantial coordination across the national-county institutional architecture.

Insecticide-Treated Net Programme

Long-lasting insecticidal nets (LLINs) are one of the most cost-effective malaria-prevention interventions. The Kenya ITN programme has distributed tens of millions of nets through universal-coverage campaigns (mass net distribution targeting all households in endemic areas every 3-4 years) and continuous-distribution channels (antenatal care, child welfare clinics, school-based distribution, and the broader continuous channels). Net usage rates have increased substantially over the past two decades, with the most recent Kenya Malaria Indicator Survey documenting substantial population coverage. The ITN programme remains the principal vector-control intervention.

Indoor Residual Spraying

Indoor residual spraying (IRS) — the spraying of long-acting insecticides on indoor wall surfaces where vector mosquitoes rest — supplements ITN-based vector control in selected high-transmission areas. The IRS programme targets specific epidemiologically-justified zones with rotating insecticide use to manage vector resistance. The IRS coverage has varied with funding availability and the broader strategy adjustments.

Case Management

The malaria case-management framework provides for prompt diagnosis (with malaria rapid diagnostic tests now widely available at primary-care facilities and at community-health-volunteer level) and effective antimalarial treatment (with the artemisinin-based combination therapies including artemether-lumefantrine being the first-line treatment for uncomplicated Plasmodium falciparum malaria, and artesunate-mefloquine and dihydroartemisinin-piperaquine being alternative options). Severe malaria treatment uses parenteral artesunate or quinine in hospital settings. The case-management programme has progressively shifted from clinical-symptom diagnosis to test-confirmed treatment, improving accuracy and reducing inappropriate antimalarial use.

Prevention in Pregnancy

Intermittent Preventive Treatment in pregnancy (IPTp) using sulphadoxine-pyrimethamine — administered at each antenatal-care visit from the second trimester — substantially reduces maternal and neonatal malaria-related complications. The IPTp programme is integrated into the broader antenatal care framework. The combination of IPTp, ITN use during pregnancy, and prompt case-management for symptomatic pregnant women constitutes the principal Malaria-in-Pregnancy intervention package.

Drug and Insecticide Resistance

The Kenya malaria-control programme monitors antimalarial drug efficacy and vector-insecticide resistance through structured surveillance. The artemisinin-based combination therapies have retained substantial efficacy in Kenya, though sustained monitoring is essential given the documented emergence of artemisinin partial resistance in selected African settings. The vector-insecticide resistance to pyrethroids (the principal insecticide class used in ITN treatment) is documented and has prompted the introduction of new ITN formulations including dual-active-ingredient nets and the broader insecticide-resistance management interventions.

RTS,S Malaria Vaccine

The RTS,S/AS01 malaria vaccine — the first malaria vaccine recommended by the WHO for routine use in children — was piloted in Kenya alongside Ghana and Malawi from 2019 onward through the Malaria Vaccine Implementation Programme (MVIP). The Kenyan pilot in selected Lake Victoria-basin counties demonstrated substantial reduction in severe malaria and child mortality. The vaccine has been progressively integrated into the broader Kenya routine childhood immunisation schedule with substantial expansion of coverage. The newer R21/Matrix-M malaria vaccine, prequalified by the WHO in late 2023, offers additional vaccine options and is being progressively introduced.

Community Health Volunteers and Integrated Community Case Management

Community Health Volunteers (CHVs) — the network of community-level health workers under the Ministry of Health framework — deliver malaria-control interventions at the community level. The integrated community case management framework allows CHVs to test for malaria using rapid tests, treat uncomplicated cases with antimalarial therapy, and refer severe cases to facilities. The community-level interventions substantially extend access to malaria diagnosis and treatment particularly in remote areas.

Research and Innovation

Kenya hosts substantial malaria research infrastructure. The KEMRI-Wellcome Trust Research Programme (in Kilifi), the Walter Reed Project (Kisumu and Kombewa), the KEMRI Centre for Geographic Medicine Research (Kilifi), and the broader academic-research community conduct world-class malaria research on vector biology, vaccine development, drug-resistance monitoring, clinical management, and the broader epidemiology. The research base has produced substantial contributions to global malaria-control science.

The Path to Elimination

The 2019-2025 National Malaria Strategy targets substantial incidence and mortality reduction, with the broader long-term aspiration of malaria elimination — eliminating local transmission such that any subsequent cases are imported rather than locally-acquired. The path to elimination requires sustained intervention coverage, the addressing of insecticide and drug resistance, the integration of new tools (vaccines particularly), and the broader strengthening of the health system. The neighbouring countries' elimination progress (Zanzibar and Sao Tome have reduced malaria substantially) demonstrates that elimination is achievable with sustained commitment.

Practical Considerations for Households

For Kenyan households in endemic areas: sleep under an LLIN every night and ensure all family members are covered; seek prompt diagnosis and treatment for any feverish illness (do not assume malaria — get tested); ensure all household members complete the full prescribed antimalarial treatment course; pregnant women should attend all antenatal care visits to receive IPTp; ensure children receive the malaria vaccine where available; remove household water-storage containers and stagnant water around homes that breed mosquitoes; close house windows in the evening and use repellents in the dusk-to-dawn period.

The Bigger Picture

Malaria remains one of the most significant public-health challenges in Kenya, but the progressive reduction in mortality and morbidity through sustained intervention represents one of the most successful public-health programmes in the country's history. The combination of vector control, case management, prevention in pregnancy, surveillance, vaccine introduction, and the broader integrated programme produces tangible health and economic benefits to millions of Kenyans annually. For households in endemic areas, healthcare professionals, public-health advocates, and the broader community, the malaria-control programme remains one of the most consequential health interventions.

The Ministry of Health and the Division of National Malaria Programme publish the operational framework. The Kenya Medical Research Institute hosts the broader research infrastructure.